Merck anticipates up to $7 billion in revenue from the drug through 2022, which it says can halve the risk of hospitalization and death in high-risk patients.
Merck Sees Up To $1 Billion In Covid Antiviral Pill Sales—It Just Needs Regulatory Approval
